About UMN Pharma
UMN Pharma is a publicly listed company based in Yokohama (Japan) founded in 2004. Influenza vaccines are researched, developed, manufactured, and distributed. UMN Pharma has raised $20 million across 2 funding rounds from investors including Dai-Ichi Life, Nomura and JAFCO Group. Its focus areas include Life Sciences, Immunotherapy, Vaccine and Therapeutic.
Company details
The company was founded in 2004 in Yokohama, Japan, within the bio-pharmaceutical sector. Bio-pharmaceutical products are researched, developed, manufactured, and distributed, with a primary focus on influenza vaccines. The lead candidate UMN-0502 is being advanced in collaboration with Astellas Pharma, with plans for entry into the US market. Commercialization efforts are underway for UMN-2002, and further vaccine candidates are planned using the BEVS platform.
- Headquarters Yokohama, Japan
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website umnpharma.com
- Social LinkedIn
- Total Equity Funding$20M (USD)
in 2 rounds
- Latest Funding Round$18.9M (USD), Series C
Feb 2007
- InvestorsDai-Ichi Life
& 12 more
Funding Insights of UMN Pharma
UMN Pharma has successfully raised a total of $20M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $18.9 million completed in February 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $20M
- Total Rounds 2
- Last Round Series C — $18.9M
- First Round $1.1M
(Oct 2005)
- Investors Count 13
All 2 funding rounds of UMN Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2007 | $18.9M | Series C | – | – | |
| Oct 2005 | $1.1M | Series B | – | – |
13 investors in total: 13 institutional.
Investors in UMN Pharma
UMN Pharma has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include Dai-Ichi Life, Nomura and JAFCO Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pacific Rim Ventures is involved in unspecified business activities. | pacificrimventures.com | |||
Investments are managed in buyout and solution areas to support Japanese enterprises. | antcapital.jp | |||
Venture capital investments are provided to support innovative entrepreneurs. | orixcapital.co.jp | |||
| yedvc.co.jp | ||||
Support is provided to SMEs for capital enrichment and growth. | 1963 | sbic.co.jp | Tokyo, Japan | |
VC firm investing in Japan and the US | nvcc.co.jp | Chiyoda City, Japan | ||
AG Capital is involved in unspecified business activities. | nf-partners.co.jp | |||
Venture capital is invested in AI, energy, and various sectors. | mucap.co.jp | Tokyo, Japan | ||
Long-term investment and consultation services are provided to SMEs. | sbic-cj.co.jp | Nagoya, Japan | ||
| smbc-vc.co.jp |
Investor details for UMN Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of UMN Pharma
4 dated milestones of UMN Pharma across 8 years, from founding to its latest funding, stage changes and deals.
- Founded UMN Pharma is founded.
- Funding First funding round of $1.1M.
- Funding Latest funding round, Series C, of $18.9M.
- IPO Lists on the stock exchange (IPO).
Web traffic of UMN Pharma
Websites that share an audience with UMN Pharma (umnpharma.com).
Websites whose visitors overlap most with UMN Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| medrx.co.jp | 100% | 4.3K | #3,767,389 | View details | |
| pci-h.co.jp | 100% | 9.8K | #2,108,288 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Umn Pharma
Complete news archive for UMN Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about UMN Pharma
UMN Pharma was founded in 2004 and raised its 1st funding round 1 year after it was founded.
UMN Pharma is headquartered in Yokohama, Japan. It is registered at Yokohama, Kanagawa, Japan.
UMN Pharma is a funded company, having raised a total of $20M across 2 funding rounds to date. The company's 1st funding round was a Series B of $1.1M, raised on Oct 2005.
The company was founded in 2004 in Yokohama, Japan, within the bio-pharmaceutical sector. Bio-pharmaceutical products are researched, developed, manufactured, and distributed, with a primary focus on influenza vaccines. The lead candidate UMN-0502 is being advanced in collaboration with Astellas Pharma, with plans for entry into the US market. Commercialization efforts are underway for UMN-2002, and further vaccine candidates are planned using the BEVS platform.
UMN Pharma has 13 investors. Key investors include Dai-Ichi Life, Nomura, JAFCO Group, Pacific Rim Ventures, and Ant Capital Partners.